CY1105269T1 - Συνδυασμενη θepαπεια εναντι ογκων που πepιλαμβανει υποκατεστημενα παραγωγα ακρυλοϋλ δισταμυκινης και αναστολεις κινασης πρωτεϊνης (κιναση σepινης/θρεονινης) - Google Patents

Συνδυασμενη θepαπεια εναντι ογκων που πepιλαμβανει υποκατεστημενα παραγωγα ακρυλοϋλ δισταμυκινης και αναστολεις κινασης πρωτεϊνης (κιναση σepινης/θρεονινης)

Info

Publication number
CY1105269T1
CY1105269T1 CY20061100717T CY061100717T CY1105269T1 CY 1105269 T1 CY1105269 T1 CY 1105269T1 CY 20061100717 T CY20061100717 T CY 20061100717T CY 061100717 T CY061100717 T CY 061100717T CY 1105269 T1 CY1105269 T1 CY 1105269T1
Authority
CY
Cyprus
Prior art keywords
sepin
accepting
inhibitors
distamycin derivatives
combination therapy
Prior art date
Application number
CY20061100717T
Other languages
English (en)
Inventor
Maria Cristina Geroni
Camilla Fowst
Paolo Cozzi
Original Assignee
Nerviano Medical Sciences S.R.L.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nerviano Medical Sciences S.R.L. filed Critical Nerviano Medical Sciences S.R.L.
Publication of CY1105269T1 publication Critical patent/CY1105269T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Η παρούσα εφεύρεση παρέχει την συνδυασμένη χρήση παραγώγων ακρυλοϋλ δισταμυκίνης, ιδιαίτερα παραγώγων α-βρομο- και α-χλωρο-ακρυλοΰλ δισταμυκίνης του τύπου (I), όπως παρατίθεται στην περιγραφή, και ενός αναστολέα πρωτεΐνης κινάσης (κινάσες σερίνης/θρεονίνης και τυροσίνης) , στη θεραπεία όγκων. Παρέχεται επίσης η χρήση των αναφερθέντων συνδυασμών για τη θεραπεία ή την πρόληψη μετάστασης ή τη θεραπεία όγκων με αναστολή της αγγειογένεσης.
CY20061100717T 2002-01-02 2006-06-05 Συνδυασμενη θepαπεια εναντι ογκων που πepιλαμβανει υποκατεστημενα παραγωγα ακρυλοϋλ δισταμυκινης και αναστολεις κινασης πρωτεϊνης (κιναση σepινης/θρεονινης) CY1105269T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP02075052 2002-01-02
EP02787763A EP1461083B1 (en) 2002-01-02 2002-12-18 Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and protein kinase (serine/threonine kinase) inhibitors
PCT/EP2002/013092 WO2003055522A1 (en) 2002-01-02 2002-12-18 Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and protein kinase (serine/threonine kinase) inhibitors

Publications (1)

Publication Number Publication Date
CY1105269T1 true CY1105269T1 (el) 2010-03-03

Family

ID=8185508

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20061100717T CY1105269T1 (el) 2002-01-02 2006-06-05 Συνδυασμενη θepαπεια εναντι ογκων που πepιλαμβανει υποκατεστημενα παραγωγα ακρυλοϋλ δισταμυκινης και αναστολεις κινασης πρωτεϊνης (κιναση σepινης/θρεονινης)

Country Status (24)

Country Link
US (1) US20060084612A1 (el)
EP (1) EP1461083B1 (el)
JP (1) JP2005516025A (el)
KR (1) KR20040078118A (el)
CN (1) CN1617744A (el)
AT (1) ATE321572T1 (el)
AU (1) AU2002352090B8 (el)
BR (1) BR0215454A (el)
CA (1) CA2472008C (el)
CY (1) CY1105269T1 (el)
DE (1) DE60210329T2 (el)
DK (1) DK1461083T3 (el)
ES (1) ES2263835T3 (el)
HU (1) HUP0402639A3 (el)
IL (2) IL162820A0 (el)
MX (1) MXPA04006543A (el)
NO (1) NO20043217L (el)
NZ (1) NZ533854A (el)
PL (1) PL371179A1 (el)
PT (1) PT1461083E (el)
RU (1) RU2328306C2 (el)
SI (1) SI1461083T1 (el)
WO (1) WO2003055522A1 (el)
ZA (1) ZA200405290B (el)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2493023C (en) * 2002-07-30 2012-01-31 Zentaris Gmbh Use of alkylphosphocholines in combination with antitumor medicaments
US8383605B2 (en) 2002-07-30 2013-02-26 Aeterna Zentaris Gmbh Use of alkylphosphocholines in combination with antimetabolites for the treatment of benign and malignant oncoses in humans and mammals
DK1868599T3 (da) * 2005-04-08 2010-02-15 Nerviano Medical Sciences Srl Antitumor-kombination omfattende substituerede acryloyl-distamycin-derivater og antistoffer, der hæmmer vækstfaktorer og deres receptorer
CA2794513A1 (en) 2010-03-31 2011-10-06 Aeterna Zentaris Gmbh Perifosine and capecitabine as a combined treatment for cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274576B1 (en) * 1995-06-27 2001-08-14 The Henry Jackson Foundation For The Advancement Of Military Medicine Method of dynamic retardation of cell cycle kinetics to potentiate cell damage
GB9615692D0 (en) * 1996-07-25 1996-09-04 Pharmacia Spa Acryloyl substituted distamycin derivatives, process for preparing them, and their use as antitumor and antiviral agents
GB0015444D0 (en) * 2000-06-23 2000-08-16 Pharmacia & Upjohn Spa Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and topoisomerase I and II inhibitors
GB0015447D0 (en) * 2000-06-23 2000-08-16 Pharmacia & Upjohn Spa Combined therapy against tumors comprising substituted acryloyl derivates and alkylating agents

Also Published As

Publication number Publication date
IL162820A (en) 2010-04-15
PL371179A1 (en) 2005-06-13
RU2328306C2 (ru) 2008-07-10
SI1461083T1 (sl) 2006-08-31
DK1461083T3 (da) 2006-07-10
JP2005516025A (ja) 2005-06-02
PT1461083E (pt) 2006-08-31
HUP0402639A3 (en) 2012-02-28
MXPA04006543A (es) 2004-10-04
RU2004123641A (ru) 2005-06-10
BR0215454A (pt) 2004-11-23
AU2002352090B8 (en) 2008-06-19
ATE321572T1 (de) 2006-04-15
CN1617744A (zh) 2005-05-18
EP1461083A1 (en) 2004-09-29
DE60210329T2 (de) 2006-11-30
DE60210329D1 (de) 2006-05-18
ZA200405290B (en) 2005-06-17
IL162820A0 (en) 2005-11-20
HUP0402639A2 (hu) 2005-04-28
WO2003055522A1 (en) 2003-07-10
CA2472008A1 (en) 2003-07-10
EP1461083B1 (en) 2006-03-29
US20060084612A1 (en) 2006-04-20
NZ533854A (en) 2007-05-31
NO20043217L (no) 2004-07-30
CA2472008C (en) 2009-07-28
KR20040078118A (ko) 2004-09-08
AU2002352090A1 (en) 2003-07-15
ES2263835T3 (es) 2006-12-16
AU2002352090B2 (en) 2008-05-15

Similar Documents

Publication Publication Date Title
EA201000093A1 (ru) Производные пиридазинона
CY1112206T1 (el) Παραγωγα πυριδαζινονης για την θεραπεια ογκων
EA200901601A1 (ru) Производные пиридазинона
CY1108032T1 (el) Πυρρολο υποκατεστημενης 2-ινδολινονης αναστολεις κινασης πρωτεϊνης
NO20065148L (no) Monocykliske heterocykler som kinase inhibitorer
NO20070514L (no) Pyrrolotriazin kinase inhibitorer
ATE554087T1 (de) Neue kinaseinhibitoren
EA201100334A1 (ru) Бициклические производные триазола для лечения опухолей
ATE432281T1 (de) Pyrrolotriazin-kinasehemmer
EA201001005A1 (ru) Производные 2-бензилпиридазинона в качестве ингибиторов мет киназы
EA200901603A1 (ru) Арил-эфирные производные пиридазинона
EA201001648A1 (ru) Производные пиридазинона
BR0215360A (pt) Derivados de indolina úteis como inibidores de proteìna quinase
DE60112306D1 (de) Kondensierte pyrazindionderivate als pde5 inhibitore
CY1112235T1 (el) Παραγωγα 3,6-διυδρο-2-οξο-6η-(1,3,4)-θειαδιαζινης
BRPI0407841A (pt) inibidores heterocìclicos de quinase
CY1105269T1 (el) Συνδυασμενη θepαπεια εναντι ογκων που πepιλαμβανει υποκατεστημενα παραγωγα ακρυλοϋλ δισταμυκινης και αναστολεις κινασης πρωτεϊνης (κιναση σepινης/θρεονινης)
CY1106713T1 (el) Συνδυασμενη θεραπεια εναντιον καρκινωματων η οποια περιλαμβανει παραγωγα υποκαταστημενης ακρυλοϋλ δισταμυσινης και αλκυλιωτικους παραγοντες
DK1292290T3 (da) Kombineret terapi mod tumorer omfattende substitueret acryloyl distamycinderivater og topoisomerase I og II inhibitorer
ATE293111T1 (de) Kondensierte pyrazindionderivate als pde inhibitoren
DE50311665D1 (de) Guanidinophenylalanin-verbindungen als urokinase-inhibitoren
ATE540951T1 (de) Substituierte 7,8-dihydro-1h-pyrimidoä4,5- büdiazepin-4-amine als kinase inhibitoren